We are live on ! Find out more
PALI icon

Palisade Bio

6 hedge funds and large institutions have $791K invested in Palisade Bio in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

236% more capital invested

Capital invested by funds: $235K → $791K (+$556K)

0% more funds holding

Funds holding: 66 (0)

0% more ownership

Funds ownership: 0%0% (+0%)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $4K

Holders
6
Holders Change
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
1
Reduced
Closed
4
Calls
Puts
$4K
Net Calls
-$4K
Net Calls Change
-$1K

PALI Hedge Fund Activity: Q3 2019 in Review

6 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q3 2019, worth a combined $791K — up 236% from $235K a quarter earlier.

Fund positioning in PALI was balanced in Q3 2019: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $641K. The largest seller was Vanguard Group, exiting entirely with an estimated $49K sold.

  • 6 institutional investors held Palisade Bio (PALI) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $791K of Palisade Bio stock for Q3 2019, up 236% quarter-over-quarter.
  • 4 funds opened new Palisade Bio positions in Q3 2019 and 4 closed out, a net change of 0 holders.
  • The largest Palisade Bio buyer in Q3 2019 was Sabby Management, an estimated $641K added.
  • The largest Palisade Bio seller in Q3 2019 was Vanguard Group, an estimated $49K sold.

Based on aggregated 13F filings for Q3 2019.